Scinai Immunotherapeutics Faces Nasdaq Minimum Bid Price Deficiency, Given Until September to Regain Compliance

An announcement from Scinai Immunotherapeutics ( (SCNI) ) is now available.

On March 16, 2026, Scinai Immunotherapeutics disclosed that it had received a Nasdaq notice on March 12, 2026 stating its American Depositary Shares had traded below the $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Capital Market rules. The notification does not immediately affect the listing or trading of the shares, and Scinai has until September 8, 2026 to regain compliance by lifting its ADS closing price to at least $1.00 for ten straight business days, during which it will monitor its stock and consider options to maintain its Nasdaq listing.

The company emphasized that it intends to use the 180‑day grace period provided under Nasdaq’s rules to address the deficiency and avoid potential delisting, a key concern for investors and partners relying on its continued access to U.S. capital markets. Maintaining compliance is important for Scinai’s visibility and liquidity as it develops immunology therapies and offers contract development and manufacturing services through its CDMO subsidiary.

The most recent analyst rating on (SCNI) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Scinai Immunotherapeutics stock, see the SCNI Stock Forecast page.

Spark’s Take on SCNI Stock

According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.

The score is held back primarily by weak financial performance—persistent operating losses and continued cash burn despite recent balance sheet improvement. Technicals are a moderate positive with the stock trading above key short-term averages and mildly positive momentum, while valuation is constrained by a negative P/E and no dividend support.

To see Spark’s full report on SCNI stock, click here.

More about Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing innovative immunology therapies, advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also operates Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical firms.

Average Trading Volume: 47,171

Technical Sentiment Signal: Sell

Current Market Cap: $605.6K

For detailed information about SCNI stock, go to TipRanks’ Stock Analysis page.